Holen Sie sich die Stockscreener-App
1.95
1.56%
0.03
Handel nachbörslich:
1.94
-0.01
-0.51%
Schlusskurs vom Vortag:
$1.92
Offen:
$1.98
24-Stunden-Volumen:
12.70M
Relative Volume:
1.70
Marktkapitalisierung:
$639.40M
Einnahmen:
$4.41M
Nettoeinkommen (Verlust:
$-67.85M
KGV:
-8.636
EPS:
-0.2258
Netto-Cashflow:
$-57.15M
1W Leistung:
-14.85%
1M Leistung:
+4.84%
6M Leistung:
+28.29%
1J Leistung:
+172.84%
1-Tages-Spanne:
$1.93
$2.11
1-Wochen-Bereich:
$1.79
$2.30
52-Wochen-Spanne:
$0.57
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.95 | 629.56M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
Ocugen Shares Drop as Eye Disease Gene Therapy Shows Delays in Phase II Trial - Bitget
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - The Globe and Mail
Noble Capital raises Ocugen stock price target on phase 2 results By Investing.com - Investing.com Australia
Ocugen Lines Up Phase III Macular Degeneration Study For Gene Therapy OCU410 - Citeline News & Insights
OCGN: HC Wainwright & Co. Raises Price Target to $10.00, Maintai - GuruFocus
Noble Capital raises Ocugen stock price target on phase 2 results - Investing.com
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout - Yahoo Finance
H.C. Wainwright raises Ocugen stock price target on gene therapy data - Investing.com
HC Wainwright Increases Ocugen (NASDAQ:OCGN) Price Target to $10.00 - MarketBeat
10 best high-risk penny stocks to buy right now - MSN
why-did-dpro-stock-crash-after-hours-today - Stocktwits
Ocugen (OCGN) Has A Healthy Cash Position For 2026 - Insider Monkey
Ocugen (OCGN) Shares Tumble After Phase 2 Trial Data Release - GuruFocus
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months - MarketBeat
Ocugen (NASDAQ:OCGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Ocugen’s Tumultuous Chapter: Earnings, Strategies, and Market Reactions - StocksToTrade
Ocugen Reports Positive Phase 2 Data for OCU410 Therapy - TipRanks
Ocugen’s Strategic Directions Amid Economic Challenges - timothysykes.com
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (NASDAQ: OCGN) reports strong Phase 2 OCU410 results in geographic atrophy - Stock Titan
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
OCU410 Phase II data show significant reduction in lesion size at 12 months - The Pharma Letter
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Benzinga
Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA - Traders Union
Ocugen stock falls 5% despite positive gene therapy trial data - Investing.com
Ocugen (OCGN) Reports Promising Phase 2 Results for Gene Therapy OCU410 - GuruFocus
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce? - Stocktwits
Ocugen stock falls on trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 31% lesion reduction in gene therapy trial By Investing.com - Investing.com Canada
Ocugen reports 31% lesion reduction in gene therapy trial - Investing.com
OCGN: OCU410 reduced lesion growth by 31% at 12 months in Phase 2, with no serious safety issues - TradingView
Ocugen, Inc. Reports Phase 2 Results for OCU410 Showing 31% Reduction in Geographic Atrophy Lesion Growth After 12 Months - Quiver Quantitative
One-shot gene therapy cut eye-lesion growth 31% in dry AMD trial - Stock Titan
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge - Yahoo Finance
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen a new buy at Canaccord on pipeline for retinal diseases - MSN
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks - Yahoo Finance
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy - Ocugen, Inc.
Ocugen (NASDAQ:OCGN) Shares Gap UpShould You Buy? - MarketBeat
Ocugen's Dose Dilemma: A Risky Bet on Gene Therapy Clarity - Bitget
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy - Bitget
Ocugen To Present Full Phase 2 ArMaDa Data Fo... - Benzinga
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT - GlobeNewswire
Ocugen, Inc.(NasdaqCM: OCGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ocugen Secures Crucial Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Earnings Risk: Will Ocugen Inc stock recover after earnings2026 Review & Safe Entry Momentum Tips - baoquankhu1.vn
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):